David S. Baldwin (born 25 August 1960 in London) is a British psychiatrist and academic, currently serving as professor of psychiatry in the Faculty of Medicine at the University of Southampton, UK[1] . His research focuses on neurobiological and psychological factors in mood and anxiety disorders, aiming to improve treatment outcomes through innovative clinical approaches and trial design.
David Baldwin completed his MB BS at the University of London in 1984. He subsequently earned his FRCPsych from the Royal College of Psychiatrists in 2002, followed by a DM from the University of Southampton in 2004. In 2015, he obtained an MA from Birkbeck College, University of London[2] .
Baldwin has held several positions at the University of Southampton, beginning as a senior lecturer in psychiatry from 1994 to 2006, then advancing to reader in psychiatry from 2006 to 2010. Since 2010, he has served as professor of psychiatry in the Faculty of Medicine. He is also an honorary professor of psychiatry at the University of Cape Town, South Africa, and an honorary consultant psychiatrist at the Mood and Anxiety Disorders Service, Southern Health NHS Foundation Trust, Southampton, UK.
Baldwin's research focuses on anxiety and depression, with a multidimensional approach that integrates neurobiological and psychological factors. His work aims to improve outcomes in mood and anxiety disorders through various avenues:
Baldwin is involved in the European College of Neuropsychopharmacology (ECNP)[3], serving as chair of the Educational Committee and Executive Committee member from 2022 to 2025. He has also served as the president of the British Association for Psychopharmacology, president of the Depression Alliance, medical patron of Anxiety UK, editor-in-chief of Human Psychopharmacology, editorial board member of Neuroscience Applied, and member of the ECNP Anxiety Network, as well as authoring some 500 scientific papers[4] .
Baldwin is a fellow of the Royal College of Psychiatrists, the Royal Society of Arts, Advance HE (formerly the Higher Education Academy), and the European College of Neuropsychopharmacology (ECNP).